Myasthenia gravis (MG) is a rare, chronic, disabling, unpredictable, and potentially life-threatening autoimmune neuromuscular disease. There is still a lack of sufficient data from real clinical practice to better meet the needs of MG patients. What is the current situation in European countries? And how are Czech patients doing?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
